US Pat. No. 9,216,950

AGONISTS OF SRC HOMOLOGY-2 CONTAINING PROTEIN TYROSINE PHOSPHATASE-1 AND TREATMENT METHODS USING THE SAME

NATIONAL TAIWAN UNIVERSIT...

1. A compound which is represented by Formula II(b) or II(c)

wherein R4, R5 and R6 are independently hydrogen, hydroxyl, optionally substituted alkoxyl, optionally substituted thioalkoxy, optionally substituted
lower alkenyl, optionally substituted low alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl,
optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroarakyl,
—(C)qNHS(O)2Rc, or —(C)r(X)NHRd;

wherein at least one R4, R5, or R6 is not hydrogen;

wherein Rc, and Rd are independently hydrogen, halo, hydroxyl, optionally substituted alkoxyl, optionally substituted thioalkoxy, optionally
substituted alkyl, optionally substituted lower alkenyl, optionally substituted low alkynyl, optionally substituted cycloalkyl,
optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted
heteroaryl, optionally substituted heteroarakyl;

X=O or S; and
q, r=0, 1, or 2.
US Pat. No. 9,211,303

SELECTIVE REDUCTION OF THE DELETERIOUS ACTIVITY OF EXTENDED TRI-NUCLEOTIDE REPEAT CONTAINING GENES

National Yang-Ming Univer...

1. A method of selectively reducing the deleterious activity in a cell of a target gene comprising a mutant extended trinucleotide
repeat domain, the method comprising:
providing in the cell an effective amount of an agent that selectively reduces transcription of the mutant extended trinucleotide
repeat domain of the target gene in the cell to selectively reduce the deleterious activity of the target gene in the cell,
wherein the agent is a SPT4 protein inhibitory agent.

US Pat. No. 9,789,214

RADIOLABELED ACTIVE TARGETING PHARMACEUTICAL COMPOSITION AND THE USE THEREOF

INSTITUTE OF NUCLEAR ENER...

1. A radiolabeled active targeting pharmaceutical composition, comprising:
a bioconjugate, comprising a biomolecule and a metal nanoparticle, and an intercalating agent, wherein the biomolecule is
C225 antibody, the intercalating agent is 1,4,7,10-Tetraazacyclotetradecane-1,4,7,10-Tetraacetic acid (1,4,7,10-Tetraazacyclotetradecane-N,N?,N?,N??-Tetraacetic
acid, DOTA); and the metal nanoparticle is Au nanoparticle; and

a radionuclide, which is indium.
US Pat. No. 9,465,032

METHOD OF USING ANTIBODY-LIPOSOME COMPLEXES FOR SELECTING A POOL OF MOLECULES

SCINOPHARM TAIWAN LTD., ...

1. A method for selecting a pool of molecules comprising the steps of:
(a) providing a pool comprising a multiplicity of different antibodies;
(b) dividing the pool of different antibodies into multiple sub-pools with each of the sub-pools comprising a plurality of
the different antibodies;

(c) loading the plurality of different antibodies of the sub-pools onto respective liposomes to form a plurality of complexes,
each of the complexes comprising a liposome with a plurality of the different antibodies bound thereto;

(d) contacting each of the sub-pool complexes with an agent; and
(e) detecting a sub-pool complex that has the agent bound thereto.

US Pat. No. 9,278,982

TARGETING HUMAN THYMIDYLATE KINASE INDUCES DNA REPAIR TOXICITY IN MALIGNANT TUMOR CELLS

NATIONAL YANG-MING UNIVER...

1. A composition for inhibiting thymidylate kinase (TMPK) comprising a therapeutically effective amount of:

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

US Pat. No. 9,090,617

AGONISTS OF SRC HOMOLOGY-2 CONTAINING PROTEIN TYROSINE PHOSPHATASE-1 AND TREATMENT METHODS USING THE SAME

NATIONAL TAIWAN UNIVERSIT...

1. A compound which is represented by Formula I

wherein R1, and R3 are independently hydrogen, and R2 is







wherein R1 is independently hydrogen; R3 is methyl; and R2 is



wherein R2 and R3 are independently hydrogen; and R1 is


US Pat. No. 9,132,158

ANTI-CANCER EXTRACT AND COMPOUNDS

National Yang-Ming Univer...

1. A fraction containing rich anti-cancer components from a plant selected from the group consisting of Graptopetalum sp., Rhodiola sp. and Echeveria sp., which is prepared by extracting the plant with dimethyl sulfoxide (DMSO), and then isolating by chromatography to obtain
a fraction called as HH-F3.

US Pat. No. 9,480,487

LATERAL LIGHT-EMITTING DEVICE FOR CONNECTING AN INTRA-MEDULLARY GUIDE WIRE

NATIONAL YANG-MING UNIVER...

1. A lateral light-emitting device for connecting an intra-medullary guide wire, comprising:
a main body, having a close accommodating space thereinside;
a front-end protecting unit, disposed in a front end of the main body;
a light-scattering unit, disposed in the accommodating space and arranged in back of the front-end protecting unit;
a lighting unit, disposed at a predetermined position in the accommodating space of the main body and corresponding to the
light-scattering unit so as to make a light generated by the lighting unit be capable of projecting to the light-scattering
unit, passing therethrough, and generating scattering;

a power supply unit, arranged at one end of the accommodating space of the main body to provide power to make the lighting
unit illuminate;

at least one transparent window, disposed at a side of the main body so as to make scattered light in the accommodating space
emit outwardly through the transparent window; and

a connecting unit, disposed at a distal end of the main body for connecting the lateral light-emitting device and the intra
medullary guide wire;

wherein a surface of the transparent window has a reverse cone shape with a light-reflecting surface so as to make the light
emit outwardly.

US Pat. No. 9,394,261

ARYL AMINE SUBSTITUTED PYRIMIDINE AND QUINAZOLINE AND THEIR USE AS ANTICANCER DRUGS

NATIONAL YANG-MING UNIVER...

1. An aryl amine substituted pyrimidine having a chemical structure (IV) below:

wherein R3 is


R4 is H, an aliphatic group with carbon number of 1-5, an amino-substituted aliphatic group, or a benzyl group; and

R5 is


US Pat. No. 9,220,777

ULTRASONICALLY-TRIGGERED DRUG VEHICLE WITH MAGNETIC RESONANCE IMAGING FUNCTION

NATIONAL YANG-MING UNIVER...

1. An ultrasonically-triggered drug vehicle with magnetic resonance imaging function, which comprises:
a polymeric microsphere core for carrying drug; and
a co-precipitation structure covering the polymeric microsphere core, consisting of an inorganic shell with bio- and hemo-compatibility
and independent superparamagnetic nano-particles decorating on the inorganic shell,

wherein the inorganic shell is made of a material selected from the group composed of hydroxyapatite, zinc oxide (ZnO), and
copper oxide (CuO) and broken under the ultrasound bombardment of high frequency (1-10 MH) and low power density (below 0.5
W/cm2), and the superparamagnetic nano-particles are superparamagnetic iron oxide (SPIO) nano-particles or ferric platinum
(FePt) nano-particles.

US Pat. No. 9,220,793

METHODS FOR IN VIVO IDENTIFICATION OF CANCER INITIATING CELLS BY MULTIMODALITY REPORTER GENE IMAGING

NATIONAL YANG-MING UNIVER...

1. A method for in vivo identification of remnant living cells in late-stage tumors as cancer initiating cells (CICs) in a
living rodent animal, comprising steps of:
(a) providing a multimodality reporter gene imaging system for co-expressing multiple reporter genes, wherein the multimodality
reporter gene imaging system is delivered by a piggyBac transposon system comprising a helper plasmid that encodes the piggyBac
transposase gene, and a donor plasmid comprising a constitutive gene promoter and two reporter genes for in vivo imaging the
transcription and translation activity of genes cloned at the downstream of the constitutive gene promoter and an antibiotic-resistant
cassette for transposition assay and stable clone selection;

(b) co-transfecting the donor plasmid comprising the two reporter genes and the helper plasmid into a cancer cell line;
(c) implanting the transfected cancer cells into a living rodent animal by subcutaneous (SC) inoculation;
(d) tracking the tumor progression and location of remnant living cancer cells that escape loss or death in a late-stage tumor
bearing in the rodent animal by the multimodality reporter gene imaging;

(e) isolating the remnant living cells that escape cell loss or death in a late-stage tumor for an assay of sphere formation
or cancer initiating cell biomarker genes; and

(f) identifying the remnant living cells that escape cell loss or death in a late-stage tumor as candidate cancer initiating
cells —when the amount of sphere formation and cancer initiating cell biomarker genes increase.

US Pat. No. 9,089,585

EXTRACTS OF POLYGONUM MULTIFLORUM THUNB, AND PREPARATION PROCESS AND USES OF THE SAME

NATIONAL YANG-MING UNIVER...

1. A method for treating anemia or leukopenia in a subject in need thereof, comprising administering to the subject an extract
product from the root of Polygonum multiflorum Thunb. in an amount effective to promote the proliferation of a cell type selected from the group consisting of hepatocytes,
bone marrow stem cells, bone marrow stromal cells, bone marrow hematopoietic progenitor cells, bone marrow hematogenic cells,
leukocytes, and erythrocytes, wherein the extract product from the root of Polygonum multiflorum Thunb. is a methanol extract.

US Pat. No. 9,480,458

ULTRASONIC POSITIONING DEVICE FOR EPIDURAL SPACE AND METHOD USING THE SAME

NATIONAL YANG-MING UNIVER...

1. An ultrasonic positioning method for an epidural space, comprising the steps of:
a puncturing step for placing an ultrasound needle transducer in an epidural needle and obliquely piercing the epidural needle
into a joint between two vertebras through a skin;

an advancing step for advancing the epidural needle toward the epidural space;
a positioning step for simultaneously detecting reflected ultrasonic signals from the ligamentum flavum (LF) and dura mater
(DM), monitoring a synchronous shift of the signals for LF and DM towards the tip of the epidural needle, and determining
whether a tip of the epidural needle is inserted into the epidural space by the disappearance of the LF signal;

a replacement step for removing the ultrasound needle transducer and putting an injecting catheter; and
an injection step for injecting an anesthetic into the epidural space via the injecting catheter, wherein
the ultrasound needle transducer includes a facet, and
the facet of the ultrasound needle transducer and an aperture of epidural needle are obliquely configured at a predetermined
angle such that when the epidural needle is obliquely pierced into the skin and advanced toward the epidural space, the ultrasonic
signals emitted from the ultrasound needle transducer substantially perpendicularly hit a tissue layer of the ligamentum flavum
and the dura mater.

US Pat. No. 9,433,365

SYSTEM AND METHOD FOR INDENTIFYING ROTORS IN FRACTIONATED SIGNALS IN PERSISTENT ATRIAL FIBRILLATION ABLATION

National Yang-Ming Univer...

1. A computer-assisted method for quantitative characterizing atrial fibrillation in a patient, comprising:
recording unipolar atrial fibrillation (AF) signals from multiple sites in a patient's atria using a plurality of probes;
calculating bipolar electrograms using unipolar AF signals recorded at adjacent sites by an analyzer in connection with the
probes, wherein the analyzer includes an analog-to-digital converter;

extracting an envelope function from the filtered bipolar electrograms using one-dimensional order statistic filtering by
the analyzer;

applying Empirical Mode Decomposition to remove a background from the envelope function of the bipolar electrogram signal
to obtain an envelope function of the filtered bipolar electrogram signal;

applying Hilbert transform to the envelope function of the filtered bipolar electrogram signal to obtain a time series of
instantaneous phases of the filtered bipolar electrogram signal;

displaying a spatial diagram of the instantaneous phases in the patient's atria at one or more times in the time series on
a display in connection with the analyzer, wherein the spatial diagram is based on the multiple sites in a patient's atria
probed by the plurality of probes;

highlighting a graphical area in the spatial diagram of the instantaneous phases to show movements of the graphical area on
the display;

demonstrating a rotational movement of the graphical area to show existence of a rotor region in the spatial diagram of the
instantaneous phases obtained from the patient's atria, comprising:

calculating a map of the instantaneous phases in the envelope function of the filtered bipolar electrogram signal in the patient's
atria; and

calculating phase shifts at different positions around a center point relative to a phase at the center point, wherein the
different positions are at substantially the same distance to the center point;

identifying the rotor region in the patient's atria if the phase shifts at the different positions rotates around the center
point; and

overlaying the rotor region on a map of the patient's atria on the display to locate the rotor region in the patient's atria
to allow therapy to be delivered to the located rotor region in the patient's atria, which increases the rate of successful
procedural AF terminations.

US Pat. No. 9,291,692

BLOOD-BRAIN BARRIER RECOVERY CURVE ASSESSMENT METHOD AND SYSTEM

NATIONAL YANG-MING UNIVER...

1. A method of assessing the blood-brain barrier recovery curve, comprising:
providing an ultrasound contrast agent to a subject;
applying an ultrasound to a brain target area of the subject to open the blood-brain barrier;
applying the ultrasound to the brain target area of the subject at different time points with a dynamic contrast-enhanced
MRI (DCE-MRI);

using DCE-MRI for the whole brain imaging to obtain DCE-MRI image signals of brain permeability on the target and non-target
area at different time points;

analyzing the obtained DCE-MRI image signals and using general kinetic model (GKM) to calculate the permeability constant
Ktrans at different time points; and

calculating the permeability constant Ktrans decay rate by using a permeability constant Ktrans equation (III):

Ktrans(t)=Ktranssonication×exp(?a×t)+Ktransnon-sonication×exp(?b×t)  (III)

and to obtain a blood-brain barrier recovery curve;
wherein, the Ktrans(t) is the permeability constant of the drug in the target area at time of t; Ktranssonication is the permeability constant of drug in the target area at t=0 after ultrasonic irradiation; Ktransnon-sonication is the permeability constant of drug in the non-target area at t=0 without ultrasonic irradiation; and the values a and b
are estimated parameters derived from the recovery curve.

US Pat. No. 9,862,947

SELECTIVE REDUCTION OF THE DELETERIOUS ACTIVITY OF EXTENDED TRI-NUCLEOTIDE REPEAT CONTAINING GENES

The Board of Trustees of ...

1. A method of reducing the deleterious activity in a cell of a target gene comprising a mutant extended trinucleotide repeat
domain, the method comprising:
providing in the cell an effective amount of an SPT4 modulatory agent that reduces the deleterious impact of the target gene
in the cell.

US Pat. No. 9,511,104

ANTI-CANCER EXTRACT AND COMPOUNDS

NATIONAL YANG-MING UNIVER...

1. An extract with anti-cancer activity, which is extracted with dimethyl sulfoxide (DMSO) from a plant of Graptopetalum sp., Rhodiola sp. or Echeveria sp.

US Pat. No. 9,248,143

COMPOUNDS AND METHODS FOR ENHANCING ERYTHROPOIESIS

NATIONAL YANG-MING UNIVER...

1. A method for treating renal disease in a subject in need thereof, comprising:
administering to the subject an effective amount of the compound of Formula I:

wherein R is a glycosyl group.

US Pat. No. 9,510,760

METHOD FOR ESTIMATING CENTRAL AORTIC PULSE PRESSURE BY CUFF PRESSURE PULSE WAVE OSCILLATION SIGNALS AND DEVICE THEREOF

National Yang-Ming Univer...

1. A novel sphygmomanometer for directly estimating central aortic pulse pressure by a pressure pulse wave oscillation signal
of a cuff, comprising:
(a) a control means for controlling a pressure of the cuff, which is used to control the proceeding of pressurization, maintenance
and decompression in a measured location of the cuff;

(b) at least one recording and storing means for recording and storing the pressure pulse wave oscillation signal of the cuff
comprising a waveform of the pressure pulse wave oscillation signal of the cuff; and

(c) a processing means for analyzing the recorded and stored waveform of the pressure pulse wave oscillation signal of the
cuff to obtain values of a plurality of predicting variables, and calculating the central aortic pulse pressure in real time
by substituting the values of the plurality of predicting variables into the following equation:

a+b*ESP+c*As+d*Ad+e*DBP+f*HR,
wherein
A. the equation is stored in the at least one storing means, end-systolic pressure (ESP), area under a pressure tracing in
systole (As), area under a pressure tracing in diastole (Ad), diastolic blood pressure (DBP) and heart rate (HR) are the plurality
of predicting variables, and a is a constant and b, c, d, e and f are variable coefficients, and

B. the equation is obtained by the following steps:
(i) measuring a plurality of pressure pulse wave oscillation signals in the cuff, one or more brachial systolic blood pressures,
and one or more diastolic blood pressures, wherein each pressure pulse wave oscillation signal comprises a waveform of the
pressure pulse wave oscillation signal in the cuff;

(ii) averaging the waveforms of the measured pressure pulse wave oscillation signals and calibrating an averaged waveform
by using the systolic blood pressures and the diastolic blood pressures;

(iii) analyzing the calibrated waveform of the pressure pulse wave oscillation signals to obtain a plurality of characteristic
signal values serving as the plurality of predicting variables; and

(iv) obtaining the constant a and the variable coefficients b, c, d, e, and f by linear regression analysis.

US Pat. No. 9,858,690

COMPUTED TOMOGRAPHY (CT) IMAGE RECONSTRUCTION METHOD

National Yang-Ming Univer...

1. A computed tomography (CT) image reconstruction method, comprising the steps of:
Collecting all the different orientations corresponding to a projection of the data by using a center line, between central
of detector and ray source, when an imaging system goes around an object every predetermined angle, and the data are recorded
into geometric parameters of the imaging projection system, then the directions of the geometric parameters of the system
are created as a set of three-dimensional spatial image reconstruction information;

Building the imaging system of the virtual data model and simplify its three-dimensional characteristics into a simplified
data model, and virtualize a set of data in a region of interest (ROI) as a forecast data, and finally input the data of the
region of interest (ROI) through the simplified data model to simulate the projections;

Comparing and matching the simulation projection information with the collected information on each angle of the projected
image, and calculating a difference value;

Processing iterative calculation of back-projection by the difference value;
Correcting the original three-dimensional image reconstruction information by the difference between the values of the back-projection;
Verifying the difference value whether is less than a predetermined difference value to decide to run the steps to begin or
not; and

Outputting the reconstructed image from all directions of the resulting simulated projection data to form a three-dimensional
imaging volume.

US Pat. No. 9,873,721

FLUORESCENT FUSION PROTEIN

National Yang-Ming Univer...

1. A fluorescent fusion protein comprising
a first fluorescent protein with a first emission wavelength, wherein the first fluorescent protein is mPlum;
a linker peptide linking the C-terminal of the first fusion protein, wherein the linker peptide has a sequence of SEQ ID:
NO.:1; and

a second fluorescent protein linking the C-terminal of the linker peptide, wherein the second fluorescent protein has a second
excitation wavelength and a second emission wavelength, wherein the second fluorescent protein is IFP 1.4;

wherein the first emission wavelength overlaps the second excitation wavelength so that the second fluorescent protein exhibits
the second emission wavelength after receiving energy.

US Pat. No. 9,980,979

COMPOUNDS AND METHODS FOR ENHANCING ERYTHROPOIESIS

NATIONAL YANG-MING UNIVER...

1. A method for treating anemia in a subject in need thereof, comprising administering to the subject a pharmaceutical composition consisting essentially of an effective amount of a compound of Formula I:
(I) wherein R is a glycosyl group,
wherein the compound of Formula I is administered as a sole active ingredient.

US Pat. No. 10,147,503

PERSONALIZE EXERCISE DECISION-MAKING DEVICE AND MANIPULATING METHOD FOR PATIENTS WITH CHRONIC DISEASES

NATIONAL YANG-MING UNIVER...

1. A personalize exercise decision-making device for chronic patients, which is worn on a user's arm, comprising:a user interface, comprises:
a data input region receives a chronic medical record message and a drug administration from the user, wherein the chronic medical record message comprises date, user name, sex, age, a confirmation on the user whether suffer from coronary artery disease, heart disease, diabetes mellitus or hypertension, a confirmation on the user whether suffer from more than one chronic disease and a confirmation on the user whether has received coronary artery bypasses grafting surgery or percutaneous coronary intervention when the user has coronary artery disease, wherein the drug administration comprises a confirmation on the user whether taking M1 medicine or M2 medicine; and
a personalize exercise decision-making unit displays a real time physiological data and an appropriate exercise suggestion;
an exercise evaluation unit electrically connects to the user interface, comprises:
a processing unit determines a classification of sports by matching the chronic medical record message and the drug administration from the data input region with correspondent information of a plurality of classification of sports from a physiological data management unit; and
a physiological detection unit, detects the real time physiological data from the user, then sends the real time physiological data to the personalize exercise decision-making unit and an exercise data analysis processing unit, wherein the real time physiological data comprises a real time blood sugar level value, a real time heart rate value, a real time blood pressure value and a real time oxygenation concentration value from the user, then the user interface displays the real time physiological data;
an exercise decision unit electrically connects to the exercise evaluation unit and the user interface, comprises:
the physiological data management unit stores a plurality of classification of sports, wherein the plurality of classification of sports are classified as a diabetes mellitus with stable coronary artery disease or hypertension and taking M1 medicine, a diabetes mellitus with stable coronary artery disease or hypertension and taking M2 medicine, a diabetes mellitus without coronary artery disease or hypertension, a coronary artery disease with acute myocardial infarction or a coronary artery bypass grafting surgery and taking M1 medicine, a coronary artery disease with acute myocardial infarction or a coronary artery bypass grafting surgery and taking M2 medicine, a stable coronary artery disease or coronary artery disease with percutaneous coronary intervention and taking M1 medicine, and a stable coronary artery disease or coronary artery disease with percutaneous coronary intervention and taking M2 medicine, wherein each of classification of sports comprises the appropriate exercise suggestion and a physiological statistical data wherein the physiological statistical data comprise a limit of the systolic blood pressure, a limit of the diastolic blood pressure, a limit of the heart rate, a limit of the blood sugar and a limit of the oxygenation concentration; and
the exercise data analysis processing unit determines the appropriate exercise suggestion by corresponding the real time physiological data to the physiological statistical data belonging to the classification of sports from the processing unit, if any one of the real time physiological data is not corresponding to the physiological statistical data of the classification of sports, then the exercise data analysis processing unit sends a can not exercise suggestion, otherwise, the exercise data analysis processing unit sends the appropriate exercise suggestion to the personalize exercise decision-making unit.
US Pat. No. 9,732,323

METHODS FOR PRODUCING MATURE HEPATOCYTES

NATIONAL YANG-MING UNIVER...

1. An in vitro differentiation process for generating mature hepatocytes from human induced pluripotent stem cells in less
than 20 days, which comprises the steps of:
(a) culturing human induced pluripotent stem cells (iPSCs) in MEF-conditioned medium comprising Dulbecco's modified Eagle
medium (DMEM)/F12 supplemented with 20% knockout serum replacement, 10 ng/mL basic fibroblast growth factor, 1 mM L-glutamine,
100 ?M nonessential amino acids, 100 ?M 2-mercaptoethanol, 50 U/mL penicillin, and 50 mg/mL streptomycin to 70% confluence;

(b) replacing the MEF-conditioned medium with culture medium containing 100 ng/mL activin A, 50 ng/mL wingless-type MMTV integration
site family, member 3A (Wnt3a) and 10 ng/mL hepatocyte growth factor (HGF), and culturing the cells for 3-5 days;

(c) replacing the culture medium with hepatic commitment medium comprising knockout [KO]/DMEM containing 20% knockout serum
replacement, 1 mM L-glutamine, 1% nonessential amino acids, 0.1 mM 2-mercaptoethanol, and 1% dimethyl sulfoxide, and culturing
the cells for 4-6 days; and

(d) culturing cells from c) in Iscove's modified Dulbecco's medium (IMDM) containing 20 ng/mL oncostatin M, 0.5 ?M dexamethasone,
and 50 mg/mL insulin, transferrin, selenous acid (ITS) premix for 5-7 days to obtain differentiated hepatocytes; wherein said
differentiated hepatocytes (i) exhibit gene expression profile similar to mature hepatocytes, and (ii) have function of urea
production and glycogen storage.

US Pat. No. 10,441,540

LIPOSOMAL LUPEOL ACETATE AND THE USE THEREOF IN PREPARING DRUGS FOR RHEUMATOID ARTHRITIS

NATIONAL YANG-MING UNIVER...

1. A pharmaceutical composition comprising:a liposomal lupeol acetate for use of inhibiting osteoclastogenesis;
wherein the liposomal lupeol acetate consists of:
lupeol acetate;
an aqueous core; and
a lipid bilayer having an inner space in which the lupeol acetate is located is constructed by a phosphatidylcholine (PC) and polyethylene glycol-distearoylphosphatidylethanolamine (PEG-DSPE) and wherein the molecular ratio of the phosphatidylcholine and polyethylene glycol-distearoylphosphatidylethanolamine is 20:1 to 35:1.

US Pat. No. 10,106,766

MICROFLUIDIC BIO-REACTOR DEVICE

NATIONAL YANG-MING UNIVER...

1. A microfluidic bio-reactor device comprising:a first cell culture layer comprising an opening defined by a continuous boundary forming the opening, said first cell culture layer located on a top of a first cell culture substrate, wherein said first cell culture layer and said first cell culture substrate form an inside of a first cell culture chamber;
a microfluidic base, the microfluidic base is located on a top of the first cell culture layer and has a first channel, a second channel and holes, said first channel and said second channel are located inside an area corresponding to the inside of the first cell culture chamber, said holes are located inside an area corresponding to the first cell culture layer;
a microfluidic layer, the microfluidic layer is located on a top of the microfluidic base, and the microfluidic layer comprising:
a gas permeable layer;
a curved channel;
an inlet having a first end and a second end, the first end of the inlet being an opening and the second end of the inlet being connected to the curved channel;
a first diffusion device having a first end and a second end, the first end of the first diffusion device being connected to the curved channel and the second end of the first diffusion device being connected to the gas permeable layer, said first diffusion device has an opening which is connected to the first channel of the microfluidic base;
an air-bubble removal device having a first end and a second end, the air-bubble removal device being a vacuum channel, the first end of the air-bubble-removal device being connected to the gas permeable layer and the second end being connected to a vacuum opening, said vacuum channel is connected to the holes of the microfluidic base;
an outlet having a first end and a second end, the first end of the outlet being an opening and the second end being connected to a second diffusion device, said second diffusion device has an opening which is connected to the second channel of the microfluidic base; and
a microfluidic roof, the microfluidic roof is located on a top of the microfluidic layer.
US Pat. No. 10,835,622

MODE OF INDUCING RENAL TRANSPLANT REJECTION ON ANIMALS AND ITS MANUFACTURING APPROACH

NATIONAL YANG-MING UNIVER...

1. A method for preparing an animal model simulating a transplant rejection, which includes:(a) providing a dendritic cell, wherein the dendritic cell is obtained from a first animal subject;
(b) providing a lymphocyte, wherein the lymphocyte is selected from a second animal subject;
(c) co-culturing the dendritic cell and lymphocyte in vitro to form an activated T lymphocyte;
(d) creating an implant position in renal cortex of a third animal subject; and
(e) transplanting the activated T lymphocyte into the implant position in the renal cortex of the third animal subject;
wherein the first subject, the second subject, and the third subject are same species, and the activated T lymphocyte would attack the renal cortex after being transplanted into the implant position in the renal cortex of the third animal subject, thus a transplant rejection model in animals would be induced in the third animal subject.

US Pat. No. 10,376,280

INVERTED BOWL SHAPED ULTRASOUND PROBE STRUCTURE OF GUIDING THE PUNCTURE NEEDLE

National Health Research ...

1. An ultrasound probe structure, comprising:an ultrasound probe housing, configured to have a hollow passage in a center thereof, wherein the hollow passage is allocated disposed with a central line aligned along with a central line of the ultrasound probe housing and configured for a puncture needle configured to be placed inside and pass through coaxially;
a plurality of transducers, arranged within the ultrasound probe housing and surrounding the hollow passage, the plurality of transducers configured to have at least two different aperture diameters and operation frequencies,
wherein each of the transducers is configured as a spherical inverted bowl shape, or an inverted curved ring shape, with a respective radius of curvature configured to have its center of curvature located at a respective point on the central line of the ultrasound probe housing, the plurality of transducers configured to have at least two different radii of curvature;
wherein the aperture diameter, the radius of curvature, and the operation frequency of each of the transducers are designed or adjusted wherein each of the transducers is configured to have a respective focal zone centered at the center of curvature and configured to have a focal length along the central line of the hollow passage and a focal width across the central line of the hollow passage;
wherein the focal zones of the plurality of transducers in combination form an overall detection range for the ultrasound probe structure, wherein the overall detection range is configured to be longer and covers a larger space than the focal zone of any of the transducers, and the puncture needle configured to be guided, by at least one of the transducers at any time as it passes through the hollow passage, for an overall depth corresponding to the overall detection range; and
wherein the focal width of the focal zone of each of the transducers is adjusted by the f number and the operation frequency, wherein the f number is defined as ri/2ai, r, is the radius of curvature of the transducer, and 2ai, is the aperture diameter of the transducer.
US Pat. No. 10,188,684

METHOD FOR PREVENTING OR TREATING FUNCTIONAL GASTROINTESTINAL DISORDER BY LACTIC ACID BACTERIUM

National Yang-Ming Univer...

1. A method for treating a functional gastrointestinal disorder in a subject in need thereof, comprising administering a composition which comprises an effective amount of a Lactobacillus plantarum subsp. plantarum PS128 as the only active ingredient for treating the functional gastrointestinal disorder, which is deposited under DSMZ Accession No. DSM 28632, and a carrier, wherein the functional gastrointestinal disorder is selected from the group consisting of constipation, and functional dyspepsia.

US Pat. No. 10,590,184

PROCESS FOR A PREPARATION OF THE MODIFIED PORCINE PLASMA FIBRONECTIN FOR ENHANCE WOUND HEALING

NATIONAL YANG-MING UNIVER...

1. A method for enhanced wound healing in a subject, wherein the method comprises:a) treating porcine fibronectin with an enzyme that modifies the glycans attached to the fibronectin protein, thereby producing a porcine fibronectin with modified glycans; and
b) administering the porcine fibronectin with modified glycans to the subject.
US Pat. No. 10,202,432

DUAL TARGETING DRUG CARRIER AND APPLICATION THEREOF

NATIONAL YANG-MING UNIVER...

1. A dual targeting drug carrier consisting of a first targeting molecule and a second targeting molecule,wherein the first targeting molecule is selected from the group consisting of Arg-Gly-Asp (RGD) and RGD4C, and the second targeting molecule is selected from the group consisting of epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF),
wherein the first targeting molecule and the second targeting molecule are selected from the group consisting of RGD-EGF (SEQ ID NO: 2), RGD4C-EGF (SEQ ID NO: 3), RGD-VEGF (SEQ ID NO: 7), and RGD4C-VEGF (SEQ ID NO: 8).

US Pat. No. 10,422,795

URINARY CRYSTAL DETECTION METHOD

National Yang-Ming Univer...

1. An urinary crystal detection method, comprising steps:providing a urine sample from a patient;
adding a plurality of magnetic particles into the urine sample, the magnetic particles attaching to a plurality of urine crystals of the urine sample, wherein the magnetic particles are formed as a core, which is coated with gelatin, and the surfaces of the magnetic particles are modified by PO(OH)2 or PO43? groups to attach the urinary crystals with Ca or Mg;
providing a magnetic field to attract the magnetic particles by a magnetic separating device, and collecting the urinary crystals which are absorbed by the magnetic particles;
analyzing a Raman signal of the urinary crystals by a microscopic Raman spectroscopy unit;
comparing the peak characteristics of the Raman signal with a component information from a database, wherein the component information is a plurality of reference peak characteristics from different urinary crystals related to a plurality of urinary calculus; and
receiving a result of the urinary calculus which the reference peak characteristics is similar as the Raman signal.

US Pat. No. 10,242,590

WEARABLE GAIT TRAINING DEVICE AND METHOD USING THE SAME

NATIONAL YANG-MING UNIVER...

1. A wearable gait training device, comprising:a support member, positioned at an attachment position of a user's lower limb by a detachable manner;
a power supply unit, fixed on the support member;
a light emitting unit, configured for providing a visible light, and positioned on the support member by a manner capable of adjusting a light projection angle, and coupled to the power supply unit, in a case that the support member is attached at the attachment position, the visible light provided by the light emitting unit being projected to a ground where a front stepping point for a user's opposite lower limb is located, so as to form a stepping prompt point;
a trigger unit, contacted a sole of foot to which the support member is attached, and electrically connected to the light emitting unit, wherein in the case that the sole of foot is landed, the trigger unit activates the light emitting unit to provide the visible light, and in the case that a pressure on the sole of foot disappears, triggering of the trigger unit is interrupted and the light emitting unit is stopped providing the visible light, and a disposal position of the trigger unit is adjusted to extend a time point of appearance of the stepping prompt point.

US Pat. No. 10,198,165

SYSTEM AND METHOD OF MAPPING MEDICAL IMAGE OF SINGLE HEART CHAMBER

NATIONAL YANG-MING UNIVER...

1. A system of mapping a cardiac image of single heart chamber, comprising:a medical image interface configured to display a cardiac image acquired from a medical 3D-based image database;
an image pre-processing unit configured to provide an operator to process and correct image brightness, contrast, an angle alignment or coordinate of the cardiac image displayed in the medical image interface;
a projection unwrapping point recording unit configured to record a projection unwrapping point set by the operator for any single heart chamber by operating a coordinate axis of the medical image interface;
a slice setting unit comprising an image rendering module, a slice setting interface and a slice recording module, wherein the image rendering module is configured to render the cardiac image processed by the image pre-processing unit into the slice setting interface, to provide the operator to set a first slice and a last slice of any single heart chamber in the slice setting interface, wherein the slice recording module is configured to record the first slice, the last slice and slices between the first slice and the last slice;
a division processing unit comprising a slice load module, a division interface and a sub-area processing module, wherein the slice load module is configured to load four-chamber view images corresponding to the recorded slices into the division interface, to provide the operator to divide an area of any single heart chamber from each of the four-chamber view images in the division interface, and the divided area of any single heart chamber is defined as a sub-area, wherein the sub-area processing module is configured to calculate each of the sub-areas according to a pre-determined function, to obtain an inner border, an outer border and morphology information of each of the sub-areas; and
a mapped image establishment unit comprising an image reconstruction module and a chamber map display interface, wherein the image reconstruction module is configured to unwrap a 3D cardiac image of any single heart chamber into a 2D chamber map image of any single heart chamber by using projection manner and according to the projection unwrapping point and information of all of the sub-areas, and calculate the morphology information to obtain morphology data of any single heart chamber, wherein the chamber map display interface is configured to display the chamber map image and the morphology data.

US Pat. No. 10,092,710

METHOD OF OBTAINING A CLASSIFICATION BOUNDARY AND AUTOMATIC RECOGNITION METHOD AND SYSTEM USING THE SAME

NATIONAL YANG-MING UNIVER...

1. A determining method of a classification boundary for limiting an axial depth in an epidural puncture, comprising:(a) obtaining a plurality of tomographic images from different axial depths of a tissue where a puncturing end is, wherein the tissue is a compartment between a dura mater and a skin;
(b) choosing a plurality of texture features of interesting from one of the tomographic images;
(c) obtaining a plurality of characteristic values by identifying intensity of the texture features in a correspondence color-scale;
(d) repeating (b) to (c), obtaining the characteristic values from each of the tomographic images with the different axial depths;
(e) mapping the characteristic values on a high dimensions' space, through Support Vector Machine method calculating a hyperplane which is best able to divide the congregation data of a first specific compartment and a second specific compartment on the high dimensions' space to distinguish different collections, and
(f) defining a first specific compartment as a Zone I and a second specific compartment is opposite to the first specific compartment as a Zone II in the graph, wherein Zone I represents the characteristic values of the tomographic images from the puncturing end located inside the spinal space and Zone II represents the characteristic values of the tomographic images from the puncturing end located outside the spinal space; and
(g) limiting the axial depth in the epidural puncture from the high dimensions' graph.
US Pat. No. 9,937,193

METHOD FOR TREATING A CANCER

NATIONAL YANG-MING UNIVER...

1. A method for treating a cancer and prolonging the overall survival of a subject suffering a cancer comprising:providing a cancer cell sample of the subject, and determining the expression of checkpoint kinase 1 (CHK-1) of the sample, wherein the attenuation of activated CHK-1 is used as a biomarker; and
administering to the subject, if the attenuation of activated CHK-1 is found in the sample, a combination of doxorubicin (Doxo) and valproic acid (VPA) at the ratio to provide synergistic cancer cell-killing effects and prolonged overall survival.

US Pat. No. 10,426,346

OPTICAL TOMOGRAPHY DIGITAL IMPRESSION IMAGING SYSTEM AND METHOD FOR USE THEREOF

NATIONAL YANG-MING UNIVER...

1. An optical tomography digital impression imaging system, comprising:an optical coherence tomography scanner, the optical coherence tomography scanner captures a plurality of optical tomography digital images, each optical tomography digital image contains a plurality of tissue regions, and a tomographic slice thickness of each tissue region in the optical tomography digital images is obtained; and
an information analysis and processing component, is electrically connected to the optical coherence tomography scanner,
wherein information analysis and processing component comprises an OCT hardware control unit, an OCT signal conversion processing unit and an OCT information analysis processing unit, and
wherein the OCT information analysis processing unit comprises a surface position judgment module, a tooth-gum boundary judgment module, a refractive index judgment module, an optical path correction module and a 3D contour construction module.
US Pat. No. 10,668,093

METHOD FOR PROLONGING THE OVER SURVIVAL OF A CANCER PATIENT

National Yang-Ming Univer...

1. A method for prolonging the overall survival of a subject in a cancer chemotherapy comprising:providing a sample of cancer cells of the subject in a cancer chemotherapy;
determining the expression of checkpoint kinase 1 (CHK-1) of the sample, wherein the attenuation of activated CHK-1 is used as a biomarker; and
administering to the subject in said cancer chemotherapy, if the attenuation of activated CHK-1 is detected in the sample, a combination of valproic acid (VA) and hydrazaline (HZ) at the ratio to provide synergistic cancer cell-killing effects of said chemotherapy and prolonged overall survival of said subject,
wherein the cancer chemotherapy includes the treatment of a chemotherapeutic agent selected from the group consisting gemcitabine, cisplatin, doxorubicin, dacarbazine and combination thereof.

US Pat. No. 10,646,195

TEST PHANTOM FOR X-RAY IMAGING

National Yang-Ming Univer...

1. A test phantom set for X-ray imaging, which comprises:a circular hollow groove provided for penetrating through a slot body, and
a plurality of test phantoms configured to a periphery of the slot body,
wherein the plurality of test phantoms further comprise:
a phantom fin, having a plurality of circular grooves and a plurality of line pairs;
an edge plate configured to one side of the phantom fin, and
a phantom configured to be placed in the circular hollow groove.
US Pat. No. 10,413,564

COMPOSITIONS AND METHODS FOR COMBATING DRUG-RESISTANT CANCERS

NATIONAL YANG-MING UNIVER...

1. A method of reducing or overcoming acquired resistance to cetuximab in a patient, the method comprising administering to the patient a composition comprising a peptide that comprises an amino acid sequence of QDGLYYLYCLVGYR (SEQ ID NO: 5) or ERVYVNISH (SEQ ID NO: 9) or a combination thereof.

US Pat. No. 10,918,417

PEDICLE SCREW SYSTEM WITH SINGLE PLANE MOTION AND AXIAL ROTATION

NATIONAL YANG-MING UNIVER...

1. A pedicle screw assembly, comprising:a screw head including a U-shaped cavity and having a longitudinal axis therethrough, wherein the U-shaped cavity is formed through an inner wall of the screw head and comprises:
a first opening formed through an upper portion of the U-shaped cavity;
a second opening, coaxial with the first opening, formed through a lower portion of the U-shaped cavity and in communication with the first opening, the second opening being slit-shaped;
an arc-shaped dimple disposed between the first opening and the second opening; and
an engaging groove disposed on a bottom surface of the arc-shaped dimple;
a screw body having an elongate column-shaped shaft and comprising:
an arc-shaped head disposed on a first end of the screw body;
four polygonal grooves disposed on a top part of the arc-shaped head, each of the four polygonal grooves being disposed on a respective side of four sides of a top part of the arc-shaped head such that the four polygonal grooves are arranged symmetrically about the top part of the arc-shaped head, wherein the four polygonal grooves are configured to facilitate rotation of the arc-shaped head upon application of an external force to allow the screw body to rotate; and
a thread portion disposed on a second end of the screw body, a thread of the thread portion configured to pass through the U-shaped cavity such that the thread portion is entirely exposed from the second opening,
a screw rod disposed in the U-shaped cavity and located above the arc-shaped head; and
a screw cap configured to be inserted into the first opening and disposed above the screw rod,
wherein a direction of inserting the screw rod is parallel to a diameter of the second opening,
wherein the engaging groove is configured to fix the arc-shaped head, and
wherein the arc-shaped head is rotatable in the arc-shaped dimple to allow the screw body to swing and rotate in the second opening and allow the arc-shaped head to fall into and contact the arc-shaped dimple,
wherein the screw body is able to swing offset from the longitudinal axis of the screw head by 30 degrees through the second opening,
wherein the screw body swings and rotates restrictively in a single specific plane through the second opening to provide the pedicle screw assembly to perform a vertebral body de-rotation.

US Pat. No. 10,667,780

CONTRAST CARRIER DEVICE WITH GEOMETRIC CALIBRATION PHANTOM ON COMPUTED TOMOGRAPHY

NATIONAL YANG-MING UNIVER...

1. A contrast carrier device with geometric calibration phantom on computed tomography, comprising:a front ring body with a front outer peripheral surface, the front outer peripheral surface is provided with a front correction bead;
a loading table, wherein one end of the loading table is connected with the front ring body;
a rear ring body, the rear ring body is oppositely arranged at the other end of the front ring body connected to the loading table, wherein the rear ring body has a rear outer peripheral surface, the rear outer peripheral surface is provided with a rear correction bead;
a virtual axis passes through the center of the front ring body and the center of the rear ring body respectively, the front correction bead and the rear correction bead are arranged equidistantly along the virtual axis; and
a support body, the support body is provided opposite to the other end of the rear ring body connected to the loading table, so that the contrast carrier device is fixed to a tomography device, and the virtual axis coincides with a scan axis of the tomography device.

US Pat. No. 10,610,736

ELECTRIC WALKING ASSISTANCE DEVICE FOR FACILITATING GAIT ACTIVITY AND THE APPLICATION METHOD THEREOF

NATIONAL YANG-MING UNIVER...

1. An electric walking assistance device for facilitating gait activity, comprising:a support member comprising at least one movable component, wherein the at least one movable component enables the support member to move horizontally;
a user area where a user can stand, wherein the user area is a ground area adjacent to the support member;
at least one gait monitoring module, wherein the at least one gait monitoring module is on the support member, the user's body, an arbitrary point within the detection range covering a range of user activities or any combinations thereof, and the at least one gait monitoring module obtains at least one gait characteristic data via a monitoring means and is capable of transmitting the at least one gait characteristic data;
at least one gait assisting module, wherein the at least one gait monitoring module is on the support member, the user's body, an arbitrary point within the detection range covering a range of user activities or any combinations thereof, and the at least one gait assisting module is capable of receiving an instruction message and is capable of providing the user with at least one notification based on the content of the instruction message to assist the user in performing a gait activity; and
a control system on the support member, wherein the control system is electrically connected or communicatively connected to both the at least one gait assisting module and the at least one gait monitoring module, and the control system receives the at least one gait characteristic data transmitted by the at least one gait monitoring module, transforms the at least one gait characteristic data into the instruction message, and transmits the instruction message to the at least one gait assisting module.

US Pat. No. 10,314,862

HYPOXIA-CULTURED MESENCHYMAL STEM CELLS FOR TREATING ATHEROSCLEROTIC LESIONS

National Yang-Ming Univer...

1. A method for treating an atherosclerotic lesion, comprising administering a subject in need thereof a therapeutically effective amount of a composition comprising hypoxia-cultured mesenchymal stem cells (MSCs) secreting cytokine IL8 to restore the endothelial function, wherein the atherosclerotic lesion is selected from a group consisting of coronary atherosclerosis, cerebral atherosclerosis, aortic atherosclerosis, and renal artery atherosclerosis.

US Pat. No. 10,219,686

MEDICAL BITE BLOCK

National Yang-Ming Univer...

1. A medical bite block, which is integrated as one-piece and is provided for a user to bite and is inserted into the user's mouth, wherein the medical bite block includes:a through passageway, which is penetrating through the medical bite block, wherein one end of the through passageway comprises an inlet opening, the other end comprises an oral opening, wherein the oral opening is configured to connect with an oral cavity of the user;
an upper biting groove, wherein an upper surface of the medical bite block provides the upper biting groove; and
a lower biting groove, wherein a lower surface of the bite block provides the lower biting groove,
wherein a second distance between the lower biting groove and the oral opening is greater than a first distance between the upper biting groove and the oral opening, thereby the lower biting groove is away from the oral cavity of the user relative to the upper biting groove and provides a first malposition between the lower biting groove and the upper biting groove,
wherein the medical bite block comprises an oral inspiration and expiration part, wherein the oral inspiration and expiration part is located inside an innerwall of the through passageway as a ring shape, and
wherein the oral inspiration and expiration part further comprises an inspiration channel and an expiration channel, wherein the inspiration channel and the expiration channel form a second malposition with each other, wherein the inspiration channel and the expiration channel are located adjacent to each other and formed as the ring shape of the oral inspiration and expiration part.

US Pat. No. 10,219,969

ELECTRIC WALKING AID AND CONTROL METHOD THEREOF

NATIONAL YANG-MING UNIVER...

1. An electric walking aid, configured to operate based on a distance between a user and the electric walking aid, and the electric walking aid comprising:a main structure comprising a base, a pair of armrests, and a support connected between the base and the armrests, and the main structure defining a user area for accommodating a user;
a moving device disposed in the main structure and configured to control the electric walking aid to move, wherein the moving device comprising at least one direction wheel and at least one drive wheel, which at least one drive wheel is controlled by a motor;
a gait sensing device disposed in the main structure and configured to sense the user's feet and output a gait characteristic message of the user by a non-contact manner, and wherein the gait characteristic message comprises a step frequency, a step length, a step speed, a step position and a first distance d1, and the first distance d1 is a straight-line distance between a specific point of the main structure and an intermediate point between the centers of the user's two soles;
an abdomen position sensing device disposed in the main structure, and configured to sense an abdomen position of the user and output an abdomen position characteristic message which contains a second distance d2 defined by a straight-line distance between the specific point of the main structure to a specific point of the user's abdomen;
a shoulder position sensing device disposed in the main structure and configured to sense a shoulder position of the user and output a shoulder position characteristic message;
an analysis module configured to collect and integrate parameters of the messages outputted from the gait sensing device, the abdomen position sensing device and the shoulder position sensing device, and analyze the parameters to output characteristic messages associated with a location of center of mass of the user, a support base area, whether the user is located within the user area, whether the user's upper body inclining forwardly, and whether the user's upper body inclining backwardly;
a control system electrically connected to the motor, the gait sensing device, the abdomen position sensing device, the shoulder position sensing device and the analysis module, and configured to perform an algorithmic program according to at least one of the characteristic messages and at least one preset parameter to obtain a calculation result, and then control the motor according to the calculation result, so that the electric walking aid is controlled to move.

US Pat. No. 10,883,142

RISK ASSESSMENT FOR PHENYTOIN-INDUCED ADVERSE DRUG REACTIONS

Chang Gung Medical Founda...

1. A method of determining and treating a human patient with epilepsy at a risk for developing an adverse drug reaction in response to phenytoin or fosphenytoin, comprising(a) detecting the patient's CYP2C and HLA genotype by
(i) detecting the presence of a CYP2C9*3 allele by one or more oligonucleotides that specifically hybridizes to the allele; and
(ii) detecting the presence of a HLA-B*1301 allele by one or more oligonucleotides that specifically hybridizes to the allele in the sample obtained from the patient,
wherein the presence of the CYP2C9*3 and HLA-B*1301 alleles is indicative of a risk for the adverse drug reaction in response to phenytoin or fosphenytoin; and
(b) following step an anticonvulsant that is not phenytoin or fosphenytoin to the patient with epilepsy who has the CYP2C9*3 and HLA-B*1301 alleles,
wherein the adverse drug reaction in response to phenytoin or fosphenytoin is Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), or drug reactions with eosinophilia and systemic symptoms (DRESS) and said phenytoin has the following structure:

US Pat. No. 10,793,527

ADENOSINE MONOPHOSPHATE-ACTIVATED PROTEIN KINASE AGONIST

NATIONAL YANG-MING UNIVER...

1. A compound of the formula (I):
or a pharmaceutically acceptable salt thereof, wherein
R1 is an unsubstituted or substituted aromatic group; R3 is selected from the group consisting of a phenyl urea group substituted by —CF3, —Cl, —OCF3, —CH3, —C2H5, —COOMe, —COOH, or a combination thereof and a substituted
Ar is an unsubstituted or substituted phenylene group.

US Pat. No. 10,675,293

NUCLEOSIDE AGENTS FOR THE REDUCTION OF THE DELETERIOUS ACTIVITY OF EXTENDED NUCLEOTIDE REPEAT CONTAINING GENES

The Board of Trustees of ...

1. A method of reducing the deleterious impact of a target gene in a cell, the method comprising:contacting a cell with an effective amount of a nucleoside agent that reduces the deleterious impact in the cell of a target gene comprising a mutant extended nucleotide repeat (NR) domain, wherein the nucleoside agent is a compound or prodrug thereof described by the formula:

wherein:
R1, R2 and R3 are independently selected from H, halogen, OH, acyloxy, alkoxy, substituted alkoxy, thiol, thioalkoxy, substituted thioalkoxy, azido, amino, aminoacyloxy and substituted amino; and
Z is selected from a purine, an azauracil, a purine analog and a pyrimidine analog, wherein if Z is a purine or a purine analog, the 6-position of the purine is not an amino or substituted amino substituent.
US Pat. No. 10,808,063

PHOTOPOLYMER COMPOSITION AND APPLICATION THEREOF

NATIONAL YANG-MING UNIVER...

1. A photopolymer composition, comprising:5 weight percent to 15 weight percent of gelatin methacrylate (GelMA);
0.1 weight percent to 5 weight percent of a silanized biologically active additive, wherein the silanized biologically active additive comprises silanized hydroxyapatite, silanized ?-tricalcium phosphate (?-TCP), or silanized bio-active glass;
0.1 weight percent to 5 weight percent of photoinitiator; and
75 weight percent to 95 weight percent of a solvent.

US Pat. No. 10,800,732

SUBSTITUTED MALONAMIDES AND THEIR USE AS ANTIBACTERIAL DRUGS

NATIONAL TAIWAN UNIVERSIT...

1. A substituted malonamide having a chemical structure (I):
wherein R1 is
C2-6 alkyl, C2-6 alkenyl, or C3-7 cycloalkyl;R2 is
C2-6 alkyl, C2-6 alkenyl, or C3-7 cycloalkyl;R3 is selected from C3 cycloalkyl, C2-6 alkenyl, or C2-5 halogenoalkyl;
R4, R5, R6, R7, R8, R9, R10, R11, R12, and R13 are independently selected from hydrogen, C1-5 alkyl, C2-6 alkenyl, ethynyl, halogen, trihalogenomethyl, nitro, hydroxyl, trihalogenomethoxy, or pentafluorosulfanyl; if R3 is allyl, R1 and R2 are not 2,4-dichlorophenyl and 2,5-dichlorophenyl; if R3 is C3-5-halogenoalkyl, R1 and R2 are not independently selected from phenyl, C1-5-alkyl phenyl or halogen phenyl; if R4, R5, R6, R7, R8, R9, R10, R11, R12, and R13 are hydrogen, R3 is not allyl or dimethylallyl.
US Pat. No. 10,780,129

USE OF MESENCHYMAL STEM CELLS IN TREATING OSTEOARTHRITIS

NATIONAL YANG-MING UNIVER...

1. A method of treating osteoarthritis, comprising:administering a cell culture of hypoxic mesenchymal stem cells (MSCs) to a patient in need thereof;
wherein the cell culture are prepared by culturing MSCs in a cell medium consisting essentially of ?-MEM supplemented with FBS, ascorbate-2 phosphate, dexamethasone, and ?-glycerophosphate under hypoxic conditions containing oxygen in the amount ranging from 1% to 7% oxygen.

US Pat. No. 10,773,098

THERAPY FOR GLIOBLASTOMA MULTIFORME

National Yang-Ming Univer...

1. A method for treating a patient being afflicted with glioblastoma multiforme (GBM), said method comprising the steps of:administering a plurality of radiation enhancer-incorporated nanocarriers to a treatment site of the patient, wherein each radiation enhancer-incorporated nanocarrier is an Au-core/SiO2-shell nanoparticle wrapped by a plurality of hyaluronic acid molecules, and the radiation enhancer-incorporated nanocarriers have a concentration of 100 ?g/ml;
administering a 5-aminolevulinic acid (5-ALA) to the treatment site of the patient, wherein the 5-ALA is transformed to protoporphyrin IX (PpIX) in GBM tumor cells at the treatment site of the patient;
applying an ultrasound having a frequency of 1 MHz to the treatment site of the patient; and
applying a radiation having a single dose of 2 Gy to the treatment site of the patient,
wherein after implementation of said method, a cell viability of the GBM tumor cells is less than 50%, and a GBM cell/Astrocyte cell kill ratio of the patient is larger than 4.
US Pat. No. 10,760,077

SELECTIVE REDUCTION OF THE DELETERIOUS ACTIVITY OF EXTENDED TRI-NUCLEOTIDE REPEAT CONTAINING GENES

The Board of Trustees of ...

1. A method of assessing whether a test compound modulates the activity of a protein encoded by a target gene comprising a mutant extended trinucleotide repeat domain, the method comprising:screening a test compound with a cell which comprises a signal producing system operatively coupled to an SPT4 protein; and
detecting a signal produced by the signal producing system, wherein the signal is produced in an SPT4 transcriptional activity dependent manner to assess whether the test compound selectively modulates the SPT4 protein activity and modulates the activity of the protein encoded by the target gene.

US Pat. No. 10,751,152

JAW MOTION TRACKING SYSTEM AND OPERATING METHOD USING THE SAME

NATIONAL YANG-MING UNIVER...

1. A jaw motion tracking system, mainly comprising:an eyewear facebow static positioning device, equipped with a first plurality of light emitting devices;
a lower jaw dynamic tracking device, equipped with a second plurality of light emitting devices; and
a stereo-vision charge-coupled device, equipped with two cameras set at two sides and an embedded microprocessor, the two cameras capturing lights transmitted from the light emitting devices of the eyewear facebow static positioning device and the lower jaw dynamic tracking device and the embedded microprocessor reconstructing a three-dimensional world Euclidean coordinate;
wherein the first plurality of light emitting devices and the second plurality of light emitting devices are selected from an active light emitting device and a passive light emitting device; and
the embedded microprocessor uses a software of camera calibration to calibrate both intrinsic and extrinsic parameters of the camera of the stereo-vision charge-coupled device before reconstructing the three-dimensional world Euclidean coordinate.
US Pat. No. 10,519,319

THREE-DIMENSIONAL PRINTING METHODS AND MATERIALS FOR MAKING DENTAL PRODUCTS

NATIONAL YANG-MING UNIVER...

1. A three-dimensional printing article for making dental products, comprising a composition, wherein the composition comprises:an Ethoxylated bisphenol A dimethacrylate, a Diurethane dimethacrylate and a Triethylene glycol dimethacrylate with 20 to 80 wt %:0 to 75 wt %:0 to 10 wt % of the composition;
a toner, wherein the toner consists of ferrihydrite (III) with 0.01 to 0.05 wt % of the composition, or iron trioxide with 0.001 to 0.005 wt % of the composition; and
a photo-initiator, wherein the photo-initiator is with 0.01 to 10 wt % of the composition.